IN THE NEWS

« Previous Release | Next Release »

BOTHELL, Wash., -- Cardiac Science, a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, today announced the appointment of Dave Marver as the Company's new President and Chief Executive Officer. Mr. Marver, 41, currently serves as the Company's Chief Operating Officer and succeeds the company's current CEO, John Hinson, who is leaving the company for personal reasons, effective March 30, 2009. Mr. Marver will become CEO and replace Mr. Hinson on the Board of Directors, effective March 31, 2009.

"Under John Hinson's leadership, the company grew nearly five-fold and finished 2008 with record revenues, cash flow and a debt-free balance sheet," said Ruediger Naumann-Etienne, Chairman of the Board. "On behalf of the entire Board I want to thank him for his decade of service to the company." He added further, "We are very fortunate to have found another strong leader in Dave Marver, and the Board is very excited to work with him as CEO to take the company forward."

Mr. Marver joined Cardiac Science as its Chief Operating Officer in October 2008. Prior to joining Cardiac Science, he spent 14 years at Medtronic, where he held a number of senior leadership positions with large businesses including Cardiac Rhythm Management, Cardiac Surgery, and Diabetes. His roles at Medtronic included Vice President Strategy & Business Development, Vice President Sales, Vice President Marketing, and Vice President Product Strategy.

Mr. Marver also spent three years at Medtronic's International Headquarters, where he led commercial activities for Medtronic's Cardiac Rhythm Management business in Western Europe. In addition, he has significant experience in device informatics and connectivity, having served as US Business Director for Medtronic's Patient Management business.

Mr. Marver earned his BA from Duke University and his MBA from the Anderson School at the University of California, Los Angeles.

About Cardiac Science

Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick^®, HeartCentrix^®, Powerheart^®, and Quinton^® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT

For more information, contact (media) info@cardiacscience.com | (investors) ir@optoindia.com | +91.80.2852.8088